- Page 1 and 2:
WORLD HEALTH ORGANIZATION INTERNATI
- Page 3 and 4:
IARC MONOGRAPHS In 1969, the Intern
- Page 5 and 6:
iv IARC MONOGRAPHS VOLUME 82 3.2 Th
- Page 7 and 8:
vi IARC MONOGRAPHS VOLUME 82 SOME M
- Page 10 and 11:
IARC WORKING GROUP ON THE EVALUATIO
- Page 12 and 13:
PARTICIPANTS 5 Observer, representi
- Page 14:
PREAMBLE
- Page 17 and 18:
10 IARC MONOGRAPHS VOLUME 82 plasms
- Page 19 and 20:
12 IARC MONOGRAPHS VOLUME 82 collec
- Page 21 and 22:
14 agents present. For processes, i
- Page 23 and 24:
16 IARC MONOGRAPHS VOLUME 82 Finall
- Page 25 and 26:
18 IARC MONOGRAPHS VOLUME 82 and mi
- Page 27 and 28:
20 IARC MONOGRAPHS VOLUME 82 (c) St
- Page 29 and 30:
22 IARC MONOGRAPHS VOLUME 82 may le
- Page 31 and 32:
24 IARC MONOGRAPHS VOLUME 82 It is
- Page 33 and 34:
26 IARC MONOGRAPHS VOLUME 82 Data r
- Page 35 and 36:
28 when there is strong evidence th
- Page 37 and 38:
30 IARC MONOGRAPHS VOLUME 82 Vol. 7
- Page 40 and 41:
GENERAL REMARKS ON THE SUBSTANCES C
- Page 42 and 43:
GENERAL REMARKS ON THE SUBSTANCES C
- Page 44:
GENERAL REMARKS ON THE SUBSTANCES C
- Page 48:
SOME TRADITIONAL HERBAL MEDICINES
- Page 51 and 52:
44 which may include, for example,
- Page 53 and 54:
46 2. Use of Traditional Herbal Med
- Page 55 and 56:
48 IARC MONOGRAPHS VOLUME 82 decade
- Page 57 and 58:
50 IARC MONOGRAPHS VOLUME 82 Table
- Page 59 and 60:
52 3.2.1 Definition of herbal medic
- Page 61 and 62:
54 3.2.8 Individual supply Herbal m
- Page 63 and 64:
56 IARC MONOGRAPHS VOLUME 82 Table
- Page 65 and 66:
58 3.3.2 Germany (see Kraft, 1999;
- Page 67 and 68:
60 beyond placebo, and this informa
- Page 69 and 70:
62 3.3.5 Canada The Canadian Food a
- Page 71 and 72:
64 of adverse reactions to OTC drug
- Page 73 and 74:
66 IARC MONOGRAPHS VOLUME 82 3.3.12
- Page 75 and 76:
68 IARC MONOGRAPHS VOLUME 82 Jellin
- Page 77 and 78:
70 IARC MONOGRAPHS VOLUME 82 Simila
- Page 79 and 80:
72 IARC MONOGRAPHS VOLUME 82 Figure
- Page 81 and 82:
74 diameter of 4-6 cm or more, lobe
- Page 83 and 84:
76 1.2 Use 1.2.1 Aristolochia conto
- Page 85 and 86:
78 1.3.3 Aristolochia fangchi Compo
- Page 87 and 88:
80 1.6.2 Structural and molecular f
- Page 89 and 90:
82 chromatographic separation with
- Page 91 and 92:
84 may contain aristolochic acids.
- Page 93 and 94:
86 IARC MONOGRAPHS VOLUME 82 A bila
- Page 95 and 96:
88 received distilled water. The an
- Page 97 and 98:
90 IARC MONOGRAPHS VOLUME 82 Figure
- Page 99 and 100:
92 varied from undetectable (< 0.02
- Page 101 and 102:
94 lochic acids enhanced immune res
- Page 103 and 104:
96 4.4 Genetic and related effects
- Page 105 and 106:
Table 3 (contd) Details of study DN
- Page 107 and 108: Table 4. DNA adduct formation with
- Page 109 and 110: Table 4 (contd) Details of study Co
- Page 111 and 112: Table 5 (contd) Species Treatment I
- Page 113 and 114: Table 6. DNA adduct formation by ar
- Page 115 and 116: Table 6 (contd) Test system Assay D
- Page 117 and 118: Table 6 (contd) Test system Assay D
- Page 119 and 120: Table 7. Polymerase action on arist
- Page 121 and 122: Table 8 (contd) Test system Drosoph
- Page 123 and 124: 116 of the forestomach and lung of
- Page 125 and 126: 118 lochic acid II (three metabolit
- Page 127 and 128: 120 IARC MONOGRAPHS VOLUME 82 Che,
- Page 129 and 130: 122 IARC MONOGRAPHS VOLUME 82 Healt
- Page 131 and 132: 124 IARC MONOGRAPHS VOLUME 82 Nishi
- Page 133 and 134: 126 IARC MONOGRAPHS VOLUME 82 Schme
- Page 135 and 136: 128 IARC MONOGRAPHS VOLUME 82 Yang,
- Page 137 and 138: 130 Figure 1. Morinda officinalis H
- Page 139 and 140: 132 1.3.2 Morinda officinalis A num
- Page 141 and 142: 134 by Soxhlet extraction with ethy
- Page 143 and 144: 136 2.1 Case-control studies 2.1.1
- Page 145 and 146: 138 3. Studies of Cancer in Experim
- Page 147 and 148: 140 1,3-Dihydroxy-2-hydroxymethylan
- Page 149 and 150: 142 4.3 Reproductive and developmen
- Page 151 and 152: Table 1 (contd) Test system Result
- Page 153 and 154: 146 5.1 Exposure data 5. Summary of
- Page 155 and 156: 148 IARC MONOGRAPHS VOLUME 82 Brigg
- Page 157: 150 IARC MONOGRAPHS VOLUME 82 Nusko
- Page 161 and 162: 154 Four pyrrolizidine alkaloids ha
- Page 163 and 164: 156 Riddelliine Oral administration
- Page 165 and 166: 158 Figure 1. Metabolism of riddell
- Page 167 and 168: 160 4.3 Reproductive and developmen
- Page 169 and 170: Table 1 (contd) Test system Result
- Page 171 and 172: 164 19 H2C OH H 20 H2C C C 14 13 12
- Page 173 and 174: 166 IARC MONOGRAPHS VOLUME 82 Chan,
- Page 175 and 176: 168 IARC MONOGRAPHS VOLUME 82 Yang,
- Page 178 and 179: AFLATOXINS These substances were co
- Page 180 and 181: Aflatoxin G 2 Chem. Abstr. Services
- Page 182 and 183: Table 2. Analytical methods validat
- Page 184 and 185: 1.2 Sources, production and use 1.2
- Page 186 and 187: 1.3 Formation and occurrence 1.3.1
- Page 188 and 189: Table 4 (contd) Product Region/Coun
- Page 190 and 191: Dietary intake of aflatoxin B 1 was
- Page 192 and 193: Table 7. Occurrence of aflatoxin M1
- Page 194 and 195: Thailand (median concentration, 0.6
- Page 196 and 197: oader range of foods than had been
- Page 198 and 199: AFLATOXINS 191 (a) Estimates of afl
- Page 200 and 201: 1.5 Regulations and guidelines AFLA
- Page 202 and 203: Table 10. Summary of the principal
- Page 204 and 205: Table 10 (contd) Reference Area Uni
- Page 206 and 207: Table 11. Summary of the principal
- Page 208 and 209:
Table 11 (contd) Reference Area Stu
- Page 210 and 211:
AFLATOXINS 203 rose to 5.5 (95% CI,
- Page 212 and 213:
aflatoxin M 1. No significant corre
- Page 214 and 215:
Table 12 (contd) Reference Area Stu
- Page 216 and 217:
in central Sudan (Omer et al., 1998
- Page 218 and 219:
3.2 Oral administration of ammoniat
- Page 220 and 221:
aflatoxin M 1 resulted in tumour in
- Page 222 and 223:
days per week for four months follo
- Page 224 and 225:
AFLATOXINS 217 reduction of the dia
- Page 226 and 227:
AFLATOXINS 219 Figure 3. Metabolic
- Page 228 and 229:
GSTs, namely hGSTA1-1 and hGSTA2-2,
- Page 230 and 231:
4.2 Toxic effects 4.2.1 Humans Repo
- Page 232 and 233:
Several studies have been reported
- Page 234 and 235:
Aflatoxins were detected in 14 of 6
- Page 236 and 237:
AFLATOXINS 229 to non-HBV-infected
- Page 238 and 239:
Table 15 (contd) Region/country No.
- Page 240 and 241:
mutation in non-tumorous liver DNA
- Page 242 and 243:
Table 16. Genetic and related effec
- Page 244 and 245:
AFLATOXINS 237 aflatoxin-treated ra
- Page 246 and 247:
AFLATOXINS 239 coding for arginine.
- Page 248 and 249:
AFLATOXINS 241 during DNA replicati
- Page 250 and 251:
4.5.2 Modulation of the effects of
- Page 252 and 253:
Thus overall, there is potential fo
- Page 254 and 255:
genicity of naturally occurring mix
- Page 256 and 257:
AFLATOXINS 249 override the importa
- Page 258 and 259:
AFLATOXINS 251 Barraud, L., Guerret
- Page 260 and 261:
AFLATOXINS 253 Chen, S.-Y., Chen, C
- Page 262 and 263:
AFLATOXINS 255 EN (European Norm) (
- Page 264 and 265:
AFLATOXINS 257 Groopman, J.D. & Sab
- Page 266 and 267:
AFLATOXINS 259 IARC (1987) IARC Mon
- Page 268 and 269:
AFLATOXINS 261 Kazemi-Shirazi, L.,
- Page 270 and 271:
AFLATOXINS 263 Lamplugh, S.M., Hend
- Page 272 and 273:
AFLATOXINS 265 Montesano, R., Haina
- Page 274 and 275:
AFLATOXINS 267 Pitt, J.I., Hocking,
- Page 276 and 277:
AFLATOXINS 269 Sengstag, C., Weibel
- Page 278 and 279:
AFLATOXINS 271 Tanaka, S., Toh, Y.,
- Page 280 and 281:
AFLATOXINS 273 Wild, C.P. & Hall, A
- Page 282 and 283:
ANNEX. AFLATOXINS IN FOODS AND FEED
- Page 284 and 285:
2.1 Introduction 2. Aflatoxins Afla
- Page 286 and 287:
mination is associated mainly with
- Page 288 and 289:
Figure 1. Intervention strategies I
- Page 290 and 291:
ANNEX 283 (c) Control of aflatoxins
- Page 292 and 293:
3.2 Chemical methods The alkali pro
- Page 294 and 295:
(Figure 3) of some of the decomposi
- Page 296 and 297:
Table 3. Studies on reduction of af
- Page 298 and 299:
ANNEX 291 incidence (JECFA, 2001; s
- Page 300 and 301:
ANNEX 293 Furthermore, the reduced
- Page 302 and 303:
ANNEX 295 Cole, R.J., Hill, R.A., B
- Page 304 and 305:
ANNEX 297 JECFA (1998) Safety Evalu
- Page 306 and 307:
ANNEX 299 Pitt, J.I. & Miscamble, B
- Page 308 and 309:
FUMONISIN B 1 This substance was co
- Page 310 and 311:
et al., 1994b), liver, kidney and m
- Page 312 and 313:
FUMONISIN B 1 Table 1. Worldwide oc
- Page 314 and 315:
FUMONISIN B 1 meal, grits and flaki
- Page 316 and 317:
Since fumonisin B 1 is present in t
- Page 318 and 319:
FUMONISIN B 1 Table 3. Levels of to
- Page 320 and 321:
with freeze-dried or oven-dried die
- Page 322 and 323:
A re-evaluation of the renal pathol
- Page 324 and 325:
FUMONISIN B 1 The kinetics of absor
- Page 326 and 327:
Figure 1. Percentage cumulative rec
- Page 328 and 329:
4.2 Toxic effects 4.2.1 Humans As n
- Page 330 and 331:
FUMONISIN B 1 Because poultry are v
- Page 332 and 333:
FUMONISIN B 1 thymic cortex of the
- Page 334 and 335:
B 1/iron-treated group showed fewer
- Page 336 and 337:
FUMONISIN B 1 were decreased and th
- Page 338 and 339:
4.4.2 Experimental systems (see Tab
- Page 340 and 341:
Table 4 (contd) Test system Result
- Page 342 and 343:
FUMONISIN B 1 Figure 3. Proposed mo
- Page 344 and 345:
FUMONISIN B 1 significantly increas
- Page 346 and 347:
FUMONISIN B 1 ability of fumonisin
- Page 348 and 349:
FUMONISIN B 1 Figure 5. A model for
- Page 350 and 351:
Three lines of evidence support the
- Page 352 and 353:
aspect of all the various proposed
- Page 354 and 355:
FUMONISIN B 1 Blázquez, C., Galve-
- Page 356 and 357:
FUMONISIN B 1 Diaz, G.J. & Boermans
- Page 358 and 359:
FUMONISIN B 1 Gelderblom, W.C.A., S
- Page 360 and 361:
FUMONISIN B 1 Kim, M.S., Lee, D.-T.
- Page 362 and 363:
FUMONISIN B 1 Marasas, W.F.O. (1997
- Page 364 and 365:
FUMONISIN B 1 Ochor, T.E., Trevatha
- Page 366 and 367:
FUMONISIN B 1 Riley, R.T., Showker,
- Page 368 and 369:
FUMONISIN B 1 Shephard, G.S., Thiel
- Page 370 and 371:
FUMONISIN B 1 Thiel, P.G., Shephard
- Page 372 and 373:
FUMONISIN B 1 Wang, D.-S., Sugiura,
- Page 374 and 375:
1.1 Chemical and physical data 1.1.
- Page 376 and 377:
Table 1. Selected methods for analy
- Page 378 and 379:
1.2 Production NAPHTHALENE 371 Naph
- Page 380 and 381:
each in Spain and Turkey, three com
- Page 382 and 383:
Naphthalene has been measured in a
- Page 384 and 385:
Table 5 (contd) Industry Country Ye
- Page 386 and 387:
NAPHTHALENE 379 A median naphthalen
- Page 388 and 389:
and detected at average concentrati
- Page 390 and 391:
Naphthalene was measured in 1987-88
- Page 392 and 393:
Case reports 2. Studies of Cancer i
- Page 394 and 395:
3.2.2 Rat Groups of 49 male and 49
- Page 396 and 397:
4. Other Data Relevant to an Evalua
- Page 398 and 399:
Based on BUA (1989) and Agency for
- Page 400 and 401:
these naphthols as metabolites. The
- Page 402 and 403:
NAPHTHALENE 395 (1979) investigated
- Page 404 and 405:
NAPHTHALENE 397 Table 8. Species co
- Page 406 and 407:
that derived from the 1R,2S-oxide o
- Page 408 and 409:
NAPHTHALENE 401 induction in DBA/2
- Page 410 and 411:
NAPHTHALENE 403 were exfoliated and
- Page 412 and 413:
Male Swiss Webster mice and male Sp
- Page 414 and 415:
NAPHTHALENE 407 monooxygenases in t
- Page 416 and 417:
Airways microdissected from male Sw
- Page 418 and 419:
esult indicates that the embryotoxi
- Page 420 and 421:
Table 10 (contd) Test system Result
- Page 422 and 423:
B6C3F 1 mice given a single intrape
- Page 424 and 425:
5.3 Animal carcinogenicity data Nap
- Page 426 and 427:
NAPHTHALENE 419 American Conference
- Page 428 and 429:
NAPHTHALENE 421 naphthalene and nap
- Page 430 and 431:
NAPHTHALENE 423 Environmental Prote
- Page 432 and 433:
NAPHTHALENE 425 Carcinogens. Method
- Page 434 and 435:
NAPHTHALENE 427 Kayal, S. & Connell
- Page 436 and 437:
NAPHTHALENE 429 Nan, H.-M., Kim, H.
- Page 438 and 439:
NAPHTHALENE 431 Propper, R. (1988)
- Page 440 and 441:
NAPHTHALENE 433 Stripp, B.R., Maxso
- Page 442:
NAPHTHALENE 435 Worley, G., Erwin,
- Page 445 and 446:
438 (e) Spectroscopy data: Infrared
- Page 447 and 448:
440 Methods of isotope-dilution GC-
- Page 449 and 450:
442 IARC MONOGRAPHS VOLUME 82 produ
- Page 451 and 452:
444 1.4 Occurrence A comprehensive
- Page 453 and 454:
446 IARC MONOGRAPHS VOLUME 82 In a
- Page 455 and 456:
Table 4. Occupational exposure to s
- Page 457 and 458:
Table 4 (contd) Country and year of
- Page 459 and 460:
452 IARC MONOGRAPHS VOLUME 82 study
- Page 461 and 462:
454 Completely insulating personal
- Page 463 and 464:
456 (a) Air IARC MONOGRAPHS VOLUME
- Page 465 and 466:
458 (see monograph in this volume);
- Page 467 and 468:
460 IARC MONOGRAPHS VOLUME 82 The F
- Page 469 and 470:
462 IARC MONOGRAPHS VOLUME 82 at th
- Page 471 and 472:
Table 10. Characteristics of cohort
- Page 473 and 474:
Table 10 (contd) Reference (country
- Page 475 and 476:
468 IARC MONOGRAPHS VOLUME 82 worke
- Page 477 and 478:
470 IARC MONOGRAPHS VOLUME 82 cance
- Page 479 and 480:
472 IARC MONOGRAPHS VOLUME 82 more
- Page 481 and 482:
474 mandelic acid samples were coll
- Page 483 and 484:
476 3.1.2 Rat Groups of 50 male and
- Page 485 and 486:
478 incidence of lung tumours was s
- Page 487 and 488:
480 1968; Engström et al., 1978a,b
- Page 489 and 490:
482 IARC MONOGRAPHS VOLUME 82 Many
- Page 491 and 492:
484 Haufroid et al. (2001) examined
- Page 493 and 494:
486 (c) Metabolism IARC MONOGRAPHS
- Page 495 and 496:
488 IARC MONOGRAPHS VOLUME 82 (1.07
- Page 497 and 498:
490 IARC MONOGRAPHS VOLUME 82 high
- Page 499 and 500:
492 IARC MONOGRAPHS VOLUME 82 accor
- Page 501 and 502:
494 IARC MONOGRAPHS VOLUME 82 posit
- Page 503 and 504:
496 IARC MONOGRAPHS VOLUME 82 guine
- Page 505 and 506:
498 IARC MONOGRAPHS VOLUME 82 pancr
- Page 507 and 508:
500 Styrene caused a dose-dependent
- Page 509 and 510:
502 On the basis of these results,
- Page 511 and 512:
504 4.4 Genetic and related effects
- Page 513 and 514:
506 IARC MONOGRAPHS VOLUME 82 repor
- Page 515 and 516:
508 (iv) Protein adducts Christakop
- Page 517 and 518:
510 showed increased levels of N7-d
- Page 519 and 520:
Table 14. Genetic and related effec
- Page 521 and 522:
514 increase in the induction of mi
- Page 523 and 524:
516 IARC MONOGRAPHS VOLUME 82 The r
- Page 525 and 526:
518 Circulating styrene 7,8-oxide m
- Page 527 and 528:
520 The increased risks for lymphat
- Page 529 and 530:
522 biologically significant extent
- Page 531 and 532:
524 IARC MONOGRAPHS VOLUME 82 Berga
- Page 533 and 534:
526 IARC MONOGRAPHS VOLUME 82 Chakr
- Page 535 and 536:
528 IARC MONOGRAPHS VOLUME 82 Darra
- Page 537 and 538:
530 IARC MONOGRAPHS VOLUME 82 Flodi
- Page 539 and 540:
532 IARC MONOGRAPHS VOLUME 82 Hansc
- Page 541 and 542:
534 IARC MONOGRAPHS VOLUME 82 Karak
- Page 543 and 544:
536 IARC MONOGRAPHS VOLUME 82 Latti
- Page 545 and 546:
538 IARC MONOGRAPHS VOLUME 82 Mäki
- Page 547 and 548:
540 IARC MONOGRAPHS VOLUME 82 Mutti
- Page 549 and 550:
542 IARC MONOGRAPHS VOLUME 82 Otten
- Page 551 and 552:
544 IARC MONOGRAPHS VOLUME 82 Salom
- Page 553 and 554:
546 IARC MONOGRAPHS VOLUME 82 Sulli
- Page 555 and 556:
548 IARC MONOGRAPHS VOLUME 82 Vodic
- Page 557 and 558:
550 IARC MONOGRAPHS VOLUME 82 pheny
- Page 560 and 561:
LIST OF ABBREVIATIONS USED IN THIS
- Page 562 and 563:
LIST OF ABBREVIATIONS 555 HPRT: hyp
- Page 564 and 565:
CUMULATIVE CROSS INDEX TO IARC MONO
- Page 566 and 567:
ortho-Anisidine 27, 63 (1982); Supp
- Page 568 and 569:
CUMULATIVE INDEX 561 Beryllium fluo
- Page 570 and 571:
CUMULATIVE INDEX 563 Chlorambucil 9
- Page 572 and 573:
CUMULATIVE INDEX 565 Clomiphene cit
- Page 574 and 575:
CUMULATIVE INDEX 567 Dibenzodioxins
- Page 576 and 577:
1,4-Dimethylphenanthrene 32, 349 (1
- Page 578 and 579:
Formaldehyde 29, 345 (1982); Suppl.
- Page 580 and 581:
Hypochlorite salts 52, 159 (1991) I
- Page 582 and 583:
CUMULATIVE INDEX 575 Malondialdehyd
- Page 584 and 585:
Methylthiouracil 7, 53 (1974); Supp
- Page 586 and 587:
CUMULATIVE INDEX 579 N-Nitrosodieth
- Page 588 and 589:
CUMULATIVE INDEX 581 Paracetamol 50
- Page 590 and 591:
Pronetalol hydrochloride 13, 227 (1
- Page 592 and 593:
CUMULATIVE INDEX 585 Sodium arsenit
- Page 594 and 595:
CUMULATIVE INDEX 587 Tetranitrometh
- Page 596 and 597:
V Vat Yellow 4 48, 161 (1990) Vinbl
- Page 598 and 599:
List of IARC Monographs on the Eval
- Page 600 and 601:
Volume 61 Schistosomes, Liver Fluke